2 Stocks That Could Capitalize on the GLP-1 Boom
They aren't the most prominent names in the GLP-1 space, but they are worth a second look.
GLP-1 drugs have experienced a surge in demand in recent years, thanks to advancements in the field and an expanding list of treatable conditions. Investors are eager to capitalize on this ongoing boom, and they have ample opportunities to do so, beyond merely investing in the current leaders in the sector: Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). Two additional stocks to consider are CVS Health (NYSE:CVS) and Roche (OTC:RHHBY).
CVS Health, a prominent pharmacy chain, has demonstrated strong performance over the past 18 months. The company has successfully tackled several challenges that have impacted its profitability, such as soaring medical costs. In the second quarter, CVS Health reported a 7.3% year-over-year increase in revenue to $106.1 billion, alongside a notable 42.5% rise in adjusted earnings per share (EPS) from $1.92 to $2.58.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
